Why Some Patients Consider Switching Weight Loss Medications
Not Losing Weight On Wegovy: Understanding Your Alternative Options
When patients aren't losing weight on Wegovy as anticipated, understanding the differences between available medications becomes crucial. Wegovy contains semaglutide, a GLP-1 receptor agonist that works by mimicking your body's natural fullness hormone. Mounjaro, containing tirzepatide, takes a dual approach by targeting both GLP-1 and GIP receptors, potentially offering a different mechanism for appetite control and metabolic effects.
The key distinction lies in how these prescription-only medicines interact with your body's hormone systems. While some patients respond excellently to Wegovy's targeted GLP-1 approach, others may find Mounjaro's broader hormonal influence more suitable for their individual physiology. Both medications require careful dose escalation and ongoing clinical monitoring to optimise results.
Wegovy vs Mounjaro: Pricing and Value Comparison at EverydayMeds
Understanding the cost implications when you're not losing weight on Wegovy and considering alternatives is essential. Our Wegovy pricing starts at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. New customers can apply code FIRST40 at checkout, while returning customers use DOSE25 to reach these final prices.
Mounjaro follows a different pricing structure given its unique dosing schedule and longer maintenance phase requirements. Our Getting Started bundles, such as the Intro Duo (0.25mg & 0.5mg Wegovy) at £169.99, provide convenient dose progression without multiple orders. The Ultimate Stability Trio offers three months of 2.4mg maintenance supply at £649.99, ensuring consistent availability during your established phase.
Clinical Evidence: What Research Shows About Not Losing Weight Expectations
When patients report not losing weight on Wegovy, it's important to contextualise expectations against clinical trial data. In the STEP 1 trial (Wilding et al., NEJM, 2021), patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. However, individual responses varied significantly within this average.
The STEP 5 trial demonstrated that sustained weight management is achievable, with patients maintaining approximately clinically studied weight loss at two years. Importantly, weight regain occurred in those who discontinued treatment, emphasising that both Wegovy and Mounjaro represent long-term management tools rather than short-term solutions for patients experiencing initial disappointing results.
How Wegovy's GLP-1 Mechanism Differs from Mounjaro's Dual Action
Understanding why some patients aren't losing weight on Wegovy requires examining its specific mechanism compared to Mounjaro's approach. Wegovy works as a GLP-1 receptor agonist, reducing appetite by acting on brain centres that control hunger and promoting feelings of fullness after smaller meals. This targeted approach may reduce food cravings and help establish sustainable eating patterns. Mounjaro's tirzepatide targets both GLP-1 and GIP receptors, potentially offering broader metabolic effects that some patients find more effective. Both medications require the same commitment to lifestyle modifications, including reduced-calorie diet and increased physical activity, to achieve optimal results.
Ordering Process: Clinical Assessment for Medication Switching
If you're not losing weight on Wegovy and considering Mounjaro, our streamlined process ensures appropriate clinical oversight. Complete our 3-minute online clinical assessment, providing details about your current Wegovy experience, any side effects, and weight management goals. Our prescribers, working under GPhC registration #9012878, review applications within 3 working days (24 hours with express service). Once approved, both medications are dispatched via next-day cold-chain delivery to maintain temperature integrity. The clinical assessment ensures any medication switch is medically appropriate and considers your individual response pattern and medical history.
Storage and Practical Considerations When Comparing Options
Practical factors matter when you're not losing weight on Wegovy and evaluating alternatives. Both medications require refrigerated storage at 2–8°C before first use, but Wegovy offers superior travel flexibility with 6 weeks room temperature stability below 30°C compared to Mounjaro's 21-day limit. Both use pre-filled injection pens with similar administration techniques, though dose escalation schedules differ. Wegovy follows a structured 17-week escalation to 2.4mg maintenance, while Mounjaro offers six dose levels up to 15mg. Understanding these practical differences helps inform your decision-making process alongside clinical considerations.
Individual Response Variation: Why Not Everyone Loses Weight on Wegovy Initially
Patient response variation explains why some individuals report not losing weight on Wegovy during initial treatment phases. Genetic factors, metabolic rate, insulin sensitivity, and medication absorption can influence how effectively either Wegovy or Mounjaro works for different patients. Some may require longer dose escalation periods or different hormonal targeting to achieve optimal results.
Clinical experience suggests that patients who don't respond optimally to single GLP-1 targeting sometimes benefit from Mounjaro's dual receptor approach. However, this doesn't indicate failure with Wegovy - rather, it highlights the importance of personalised weight management strategies. Both medications are prescription-only medicines requiring ongoing monitoring and lifestyle commitment for success.
Making Your Decision: Next Steps with EverydayMeds Clinical Support
When you're not losing weight on Wegovy as expected, having access to both medication options through one trusted pharmacy simplifies your journey. Our clinical team can review your current progress, discuss realistic timelines, and support appropriate medication decisions based on your individual response pattern. Both Wegovy and Mounjaro are available with transparent pricing, discount codes applied at checkout, and comprehensive clinical oversight. Remember that weight management is a long-term commitment, and finding the right medication may require patience and professional guidance. Start your clinical assessment today at https://everydaymeds.co.uk/collections/weight-loss to explore which option might better suit your needs, with new customer discount code FIRST40 or returning customer code DOSE25 applied at checkout.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
